Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2007

Lilly Coughs Up $87M Upfront for BioMS Medical’s MS Candidate

  • Eli Lilly gained exclusive, worldwide rights to BioMS Medical's lead multiple sclerosis (MS) compound for $87 million. BioMS also stands to earn development and sales milestones of up to $410 million. The company will receive escalating royalties.

    MBP8298 is currently in two Phase III trials in secondary progressive MS and one Phase II study  in relapsing-remitting MS. Under the terms of the agreement, Lilly and BioMS Medical will collaborate on the development of MBP8298. The firms will share some development costs, with Lilly being responsible for future R&D, manufacturing, and marketing activities.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »